Searchable abstracts of presentations at key conferences in endocrinology

ea0074ncc25 | Highlighted Cases | SFENCC2021

An adrenocortical carcinoma with distinct features of 21-hydroxylase deficiency

Ly Elisa , Howell Simon , Kaushal Kalpana , Zelhof Bachar , Wahie Twesha , Ghatore Lea , Laing Ian

Adrenal carcinomas are rare with a poor prognosis, highlighting the importance of prompt investigation of adrenal incidentalomas. We report a challenging case of an adrenocortical carcinoma secreting steroids in a pattern characteristic of 21-hydroxylase deficiency, which also proved to be a histopathological enigma. A 36-year-old woman underwent investigation for right-sided loin pain. A CT showed an avidly heterogeneously enhancing circumscribed left adrenal mass measuring 6...

ea0056p140 | Endocrine tumours and neoplasia | ECE2018

Achievement of therapeutic mitotane concentrations in management of advanced adrenocortical cancer: a single centre experience in 47 patients

Bakhit Mohamed , Whitelaw Benjamin C , Gilbert Jackie , Coskeran Patsy , Diaz-Cano Salvador , Taylor David R , Taylor Norman T , Ghatore Lea , Lewis Dylan , Vivian Gillian , Sarker Debashis , Ross Paul , Davis Laura May , Clough Jennifer , Hubbard Johnathan G , Galata Gabriele , Prachalias Andreas , Schulte Klaus-Martin , Aylwin Simon J B

Introduction: Multi-modal therapy for adrenocortical carcinoma (ACC) includes surgery, therapy with the adrenolytic agent mitotane and systemic chemotherapy. Achievement of therapeutic mitotane concentrations (≥14 mg/l) has been related to improved outcomes.Aim: To evaluate the effectiveness of a defined* high dose protocol mitotane therapy in patients with advanced ACC (stages III and IV).Methods: Review of patients presenti...